Method and means for site directed therapy
The present invention relates to the field of site directed therapy. More specifically the invention relates to site directed radio therapy, and provides a method for production of radioconjugates and an apparatus for radioimmunotherapy. The method, conjugates and apparatus can be practicalized without the need for radioactive shielding and/or airtight facilities. Without these restrictions the invention provides a simple and efficient means of therapy at the bed-side of the patient.
1. A method for killing target cells in a mammal by α-particle radiotherapy, wherein said target cells are in micrometastases having a diameter of about 1 mm or less, said method comprising providing a sufficient quantity of 225 Ac to produce a therapeutically effective amount of 213 Bi through radioactive decay, binding the 225 Ac onto a substrate for immobilizing 225 Ac, eluting from the substrate 213 Bi produced by bound 225 Ac, coupling the eluted 213 Bi, substantially free of 225 Ac, to a targeting moiety to form a conjugate, said targeting moiety being selected from the group consisting of a ligand having binding specificity for a receptor associated with said target cell or a ligand fragment having binding specificity for a receptor associated with said target cells, and administering said conjugate to said mammal to effectuate specific binding of said conjugate to said target cells.
2. The method as claimed in claim 1 , wherein the conjugate is administered intermittently in fractions of the total amount of conjugate required to provide an effective amount of 213 Bi for killing said target cells in the mammal, and wherein a sufficient number of fractions of sufficient quantifies of conjugate are administered to kill essentially all target cells bound by said conjugate, the total quantity of a radiation administered to the mammal being less than the total quantity necessary to kill essentially all target cells by administering a single dose of said conjugate.
3. The method as claim in claim 1 , wherein said conjugate is administered continuously for a time sufficient to administer an effective amount of 213 Bi for killing said target cells in the mammal, and wherein a sufficient duration of continuous administration is maintained to kill essentially all target cells bound by said conjugate.
4. The method as claimed in claim 1 , wherein said ligand is a peptide.
5. A method for providing site directed radiotherapy to a pathological site in a mammal in need of such therapy, said pathological site comprising a target moiety, said method comprising providing a radioconjugate comprising of a targeting moiety bound, directly or indirectly, to an α-particle emitting radioisotope, wherein the α-particle emitting radioisotope is 225 Ac or 213 Bi, said target moiety and said targeting moiety constituting a specific binding pair, and administering to said mammal a sufficient amount of said conjugate to produce a radiotherapeutic effect at said pathological site, wherein the pathological site comprises a micrometastasis having a diameter of about 1 mm or less.
6. The method of claim 5 , wherein said pathological site comprises diseased cells.
7. The method of claim 6 , wherein said α-particle emitting radioisotope is 213 Bi.
8. The method of claim 7 , wherein said targeting moiety is a ligand having binding specificity for a cell surface receptor present on said diseased cells.
9. The method of claim 8 , wherein said ligand is a peptide.